These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 31844014)

  • 1. Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.
    Aguilera-Alonso D; Escosa-García L; Saavedra-Lozano J; Cercenado E; Baquero-Artigao F
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.
    Chiotos K; Hayes M; Gerber JS; Tamma PD
    J Pediatric Infect Dis Soc; 2020 Feb; 9(1):56-66. PubMed ID: 31872226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis.
    Fiore M; Alfieri A; Di Franco S; Pace MC; Simeon V; Ingoglia G; Cortegiani A
    Antibiotics (Basel); 2020 Jul; 9(7):. PubMed ID: 32645986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is it time to move away from polymyxins?: evidence and alternatives.
    Soman R; Bakthavatchalam YD; Nadarajan A; Dwarakanathan HT; Venkatasubramanian R; Veeraraghavan B
    Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):461-475. PubMed ID: 33009595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".
    Papp-Wallace KM; Mack AR; Taracila MA; Bonomo RA
    Infect Dis Clin North Am; 2020 Dec; 34(4):773-819. PubMed ID: 33011051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Treatment of Pandrug-resistant Klebsiella pneumoniae Infection With Ceftazidime-avibactam in a Preterm Infant: A Case Report.
    Coskun Y; Atici S
    Pediatr Infect Dis J; 2020 Sep; 39(9):854-856. PubMed ID: 32804464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017.
    Stone GG; Seifert H; Nord CE
    Int J Antimicrob Agents; 2020 Sep; 56(3):106045. PubMed ID: 32522673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam.
    Bassetti M; Peghin M; Mesini A; Castagnola E
    Infect Drug Resist; 2020; 13():1763-1773. PubMed ID: 32606826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology.
    Lasko MJ; Nicolau DP
    Curr Infect Dis Rep; 2020 Feb; 22(3):6. PubMed ID: 32034524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bloodstream Infections due to Carbapenem-Resistant
    Shen L; Lian C; Zhu B; Yao Y; Yang Q; Zhou J; Zhou H
    Microb Drug Resist; 2021 Feb; 27(2):227-233. PubMed ID: 32584202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant
    Zhou J; Yang J; Hu F; Gao K; Sun J; Yang J
    Infect Drug Resist; 2020; 13():2571-2578. PubMed ID: 32801794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New β-Lactam-β-Lactamase Inhibitor Combinations.
    Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.
    Karakonstantis S; Kritsotakis EI; Gikas A
    Infection; 2020 Dec; 48(6):835-851. PubMed ID: 32875545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.
    Li L; Li X; Xia Y; Chu Y; Zhong H; Li J; Liang P; Bu Y; Zhao R; Liao Y; Yang P; Lu X; Jiang S
    Front Pharmacol; 2020; 11():786. PubMed ID: 32547394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant
    Han R; Shi Q; Wu S; Yin D; Peng M; Dong D; Zheng Y; Guo Y; Zhang R; Hu F;
    Front Cell Infect Microbiol; 2020; 10():314. PubMed ID: 32719751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftazidime/avibactam for specified infections.
    Aust Prescr; 2020 Jun; 43(3):98-99. PubMed ID: 32675913
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy.
    Tichy E; Torres A; Bassetti M; Kongnakorn T; Di Virgilio R; Irani P; Charbonneau C
    Clin Ther; 2020 May; 42(5):802-817. PubMed ID: 32349879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoepidemiology of Ceftazidime-Avibactam Use: A Retrospective Cohort Analysis of 210 US Hospitals.
    Strich JR; Ricotta E; Warner S; Lai YL; Demirkale CY; Hohmann SF; Rhee C; Klompas M; Palmore T; Powers JH; Dekker JP; Adjemian J; Matsouaka R; Woods CW; Danner RL; Kadri SS
    Clin Infect Dis; 2021 Feb; 72(4):611-621. PubMed ID: 32107536
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Stone GG; Bradford PA; Tawadrous M; Taylor D; Cadatal MJ; Chen Z; Chow JW
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071051
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.